SMARCA4‐deficient cancer cells are highly dependent on SMARCA2 for survival, and targeting SMARCA2 in SMARCA4‐deficient cancers is expected to produce strong synthetic lethal effects [232]. This evidence concerns the gene SMARCA2 and cancer.